Enfortumab vedotin and pembrolizumab improves EFS, OS, and pCR in muscle-invasive bladder cancer
Published on 6 March 2026
Dr Matthew Galsky speaks to ecancer about results from the phase 3 KEYNOTE-B15/EV-304 trial.
The results show that perioperative enfortumab vedotin plus pembrolizumab significantly improves outcomes in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy.
Compared with standard neoadjuvant gemcitabine plus cisplatin, the combination achieved higher pathologic complete response rates (55.8% vs 32.5%) and significantly improved event-free survival (HR 0.53) and overall survival (HR 0.65).
The safety profile was consistent with previous experience. These findings support enfortumab vedotin plus pembrolizumab as a promising perioperative treatment strategy for MIBC.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.